MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 201741 | Name: Totrombopag choline

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Totrombopag, also known LGD-4665, GSK2285921 and SB559448, is an oral thromobopoietin receptor agonist, is being developed as a new generation small molecule thrombopoietin (TPO) mimetic. It is a highly selective and potent agonist of the TPO receptor and therefore induces differentiation and proliferation of megakaryocytes. The pharmacologic characteristics indicate potential therapeutic use in thrombocytopenic patients with a variety of clinical etiologies.

Chemical Structure

Totrombopag choline
Totrombopag choline
CAS#851606-62-7 (choline)

Theoretical Analysis

MedKoo Cat#: 201741

Name: Totrombopag choline

CAS#: 851606-62-7 (choline)

Chemical Formula: C30H35N9O3

Exact Mass:

Molecular Weight: 569.67

Elemental Analysis: C, 63.25; H, 6.19; N, 22.13; O, 8.43

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
376592-42-6 (free base) 851606-62-7 (choline)
Synonym
SB559448; SB 559448; SB-559448; LGD-4665; LGD4665; LGD 4665; GSK2285921; GSK-2285921; GSK 2285921; C116875; Totrombopag choline
IUPAC/Chemical Name
2-hydroxy-N,N,N-trimethylethan-1-aminium (E)-5-(3'-((1-(3,4-dimethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-yl)diazenyl)-2'-hydroxy-[1,1'-biphenyl]-3-yl)tetrazol-1-ide
InChi Key
JKVHRBKMPPIUNC-UHFFFAOYSA-N
InChi Code
InChI=1S/C25H21N8O2.C5H14NO/c1-14-10-11-19(12-15(14)2)33-25(35)22(16(3)30-33)27-26-21-9-5-8-20(23(21)34)17-6-4-7-18(13-17)24-28-31-32-29-24;1-6(2,3)4-5-7/h4-13,22H,1-3H3,(H-,27,28,29,31,32,34);7H,4-5H2,1-3H3/q-1;+1
SMILES Code
C[N+](C)(C)CCO.OC1=C(/N=N/C2C(C)=NN(C3=CC=C(C)C(C)=C3)C2=O)C=CC=C1C4=CC=CC(C5=NN=N[N-]5)=C4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not soluble in water.
Shelf Life
>5 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# 376592-42-6 (Totrombopag) 851606-62-7 (Totrombopag choline)  

Preparing Stock Solutions

The following data is based on the product molecular weight 569.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1. Fox, Norma E.; Lim, Jihyang; Chen, Rose; Geddis, Amy E. F104S c-Mpl responds to a transmembrane domain-binding thrombopoietin receptor agonist: Proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents. Experimental Hematology (New York, NY, United States) (2010), 38(5), 384-391. 2. Rice, Lawrence. Treatment of immune thrombocytopenic purpura: focus on eltrombopag. Biologics: Targets & Therapy (2009), 3 151-157. 3. Tomillero A; Moral M A Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology (2008), 30(7), 543-88. 4. Bayes M; Rabasseda X Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology (2008), 30(1), 67-99.